ASH 2021: Novel Immunocytokine Under Study in Resistant Multiple Myeloma
Posted: Friday, December 17, 2021
The preliminary results of an early-phase trial of the immunocytokine modakafusp alfa (also known as TAK-573) in patients with relapsed or refractory multiple myeloma demonstrated responses with doses starting at 0.1 mg/kg weekly, according to Dan T. Vogl, MD, of the University of Pennsylvania, Philadelphia, and colleagues. The updated results, which focused on outcomes from an expansion cohort with dosing every 4 weeks, were presented during the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 898).
“Modakafusp alfa…has shown promising antimyeloma activity in heavily pretreated patients, including patients with anti-CD38 monoclonal antibody–refractory disease and those who have received an anti-CD38 monoclonal antibody in their most recent line of treatment,” the investigators remarked. “[Administration of modakafusp alfa every 4 weeks] is feasible, and the optimal dose and potential combinations are being explored.”
Using a 3+3 dose-escalation scheme, 83 patients who had received at least three previous lines of treatment were administered modakafusp alfa in doses ranging from 0.001 to 6 mg/kg. The maximum tolerated dose was exceeded with 6 mg/kg of modakafusp alfa every 4 weeks. A total of 24 patients were treated with 1.5 mg/kg of modakafusp alfa every 4 weeks; analyses included data from this population.
Treatment-emergent adverse events of grade 3 or higher were reported in 75% of patients. Neutropenia (50%), leukopenia (38%), decreased lymphocyte count (38%), anemia (33%), and thrombocytopenia (33%) were the most frequently reported grade 3 or 4 treatment-emergent adverse events. The overall response rate was 42%, and the clinical benefit rate was 54%. The median duration of response, progression-free survival, and time to response were 7.4, 5.7, and 1.9 months, respectively. The overall response rate was 43% in patients with anti-CD38 monoclonal antibody–refractory multiple myeloma and 75% in those who received an anti-CD38 monoclonal antibody in their most recent line of therapy prior to enrollment.
Disclosure: For full disclosures of the study authors, visit ash.confex.com.
